title: Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes.
abstract: Insulin dependent diabetes (IDD) is considered to be an immune endocrinopathy as in such patients a disorder of the immune system is involved; however, up to now no data are available on the occurrence of antiphospholipid antibodies (aPL) in IDD pregnant women and on possible correlation between the presence of aPL and the high fetomaternal morbidity reported in these patients. The presence of lupus anticoagulant (LA) and of anticardiolipin antibodies (ACA) was monthly evaluated. In 35 IDD pregnant women referring within the 7 degrees week of pregnancy to the High Risk Pregnancy Medical Unit. Levels of D-dimer, fibrin degradation product, were also assayed. Twelve IDD pregnant women resulted to be aPL positive with a markedly high prevalence of positivity (34%). aPL positive did not significantly differ from aPL negative women in age, duration and severity of diabetes and in metabolic control throughout pregnancy. Pregnancy induced hypertension (PIH) and intrauterin growth retard (IUGR) were observed in 6/12 aPL positive and in only 2/23 aPL negative patients (p < 0.02). A pathological increase in D-dimer levels occurred in 6/12 aPL positive patients and in none aPL negative (p < 0.03). The high frequency of aPL positivity and its strict relation to pregnancy complications strongly support a major role for an autoimmune pathogenetic mechanism in the occurrence of feto-maternal morbidity in IDD pregnant women. The identification of this subgroup at risk for complications may be clinically relevant.
authors.affiliation: Istituto di Clinica Medica Generale e Cardiologia, University of Florence, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Boddi
authors.forename: D
authors.initials: D
authors.lastname: Prisco
authors.forename: S
authors.initials: S
authors.lastname: Fedi
authors.forename: A P
authors.initials: AP
authors.lastname: Cellai
authors.forename: A A
authors.initials: AA
authors.lastname: Liotta
authors.forename: E
authors.initials: E
authors.lastname: Parretti
authors.forename: F
authors.initials: F
authors.lastname: Mecacci
authors.forename: G
authors.initials: G
authors.lastname: Mello
authors.forename: R
authors.initials: R
authors.lastname: Abbate
mesh_terms: D000704:Analysis of Variance; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D002096:C-Peptide / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D005260:Female; D006801:Humans; D007330:Insulin Antibodies / Q000097:blood; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D008431:Maternal-Fetal Exchange / Q000276:immunology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011254:Pregnancy in Diabetics / Q000276:immunology*; D018566:Pregnancy, High-Risk / Q000276:immunology*
chemical_list: D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D002096:C-Peptide; D007330:Insulin Antibodies; D016682:Lupus Coagulation Inhibitor